Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of pertuzumab plus trastuzumab and taxanes in patients with HER2+ metastatic breast cancer:A multicenter, retrospective-prospective, observational study

Trial Profile

Safety and efficacy of pertuzumab plus trastuzumab and taxanes in patients with HER2+ metastatic breast cancer:A multicenter, retrospective-prospective, observational study

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Oct 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Docetaxel; Paclitaxel; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms G.O.N.O. SUPER
  • Most Recent Events

    • 21 Sep 2020 Final results presented at the 45th European Society for Medical Oncology Congress.
    • 05 Jun 2018 Preliminary results (As of Jan 31st 2018; n=300) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 12 Jan 2018 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top